# EDGAR Filing Document

**Accession Number:** 0001677940
**File Stem:** 0001171843-25-006027
**Filing Date:** 2025-9
**Character Count:** 11620
**Document Hash:** f709c6539afaea3a50c989d3fdf452b6
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001171843-25-006027.hdr.sgml**: 20250923

**ACCESSION NUMBER**: 0001171843-25-006027

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20250922

**ITEM INFORMATION**: Entry into a Material Definitive Agreement

**ITEM INFORMATION**: Other Events

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20250923

**DATE AS OF CHANGE**: 20250923

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** BeyondSpring Inc.
- **CENTRAL INDEX KEY:** 0001677940
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38024
- **FILM NUMBER:** 251331723

**BUSINESS ADDRESS:**
- **STREET 1:** 100 CAMPUS DRIVE, WEST SIDE, 4TH FLOOR
- **STREET 2:** SUITE 410
- **CITY:** FLORHAM PARK
- **STATE:** NJ
- **ZIP:** 07932
- **BUSINESS PHONE:** 646-528-4184

**MAIL ADDRESS:**
- **STREET 1:** 100 CAMPUS DRIVE, WEST SIDE, 4TH FLOOR
- **STREET 2:** SUITE 410
- **CITY:** FLORHAM PARK
- **STATE:** NJ
- **ZIP:** 07932

?xml version='1.0' encoding='ASCII'? Form 8-K

### UNITED STATES

### SECURITIES AND EXCHANGE COMMISSION

### Washington, D.C. 20549
_________________

### FORM 8-K
_________________

#### CURRENT REPORT

#### Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

#### Date of Report (Date of earliest event reported): September 22, 2025
_______________________________

#### BeyondSpring Inc.
(Exact name of registrant as specified in its charter)

_______________________________

---

| | | |
|:---|:---|:---|
| **Cayman Islands** | **001-38024** | **Not Applicable** |
| (State or Other Jurisdiction of Incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) |

---

#### 100 Campus Drive, West Side, 4th Floor, Suite 410

#### Florham Park, New Jersey 07932
(Address of Principal Executive Offices) (Zip Code)

#### +1 (646) 305-6387
(Registrant's telephone number, including area code)

#### Not Applicable
(Former name or former address, if changed since last report)

_______________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| Ordinary Shares, par value $0.0001 per share | BYSI | The NASDAQ Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 1.01. Entry into a Material Definitive Agreement.**

As previously disclosed, in August 2024, SEED Therapeutics Inc. ("SEED"), a clinical-stage biotechnology company pioneering rational molecular glue degraders for historically undruggable disease drivers, sold to Eisai and certain other third-party investors an aggregate of 5,647,059 of its Series A-3 Preferred Shares for an aggregate purchase price of $24 million at a cash purchase price of $4.25 per share.

On September 22, 2025, SEED entered into share purchase agreements with certain third-party investors to sell an aggregate of 1,411,761 of its Series A-3 Preferred Shares for an aggregate purchase price of $6 million at a cash purchase price of $4.25 per share. Closing under the share purchase agreements (the "second close") has completed. Upon the consummation of the second close, BeyondSpring Inc. (the "Company") and SEED Technology Limited ("SEED Technology"), a British Virgin Islands company and a majority-owned indirect subsidiary of the Company (collectively, the BYSI Entities"), is expected to own approximately 38.03% of the outstanding equity interest in SEED, calculated on an as-converted basis (excluding any shares that may be reserved under an employee stock ownership plan, or similar arrangement). The Company expects that SEED will continue to be consolidated into the financial statements of the Company since the Company remains substantive control of SEED.

This Report on Form 8-K shall not constitute an offer to sell or the solicitation of an offer to buy the Series A-3 Preferred Shares, nor shall there be any offer, solicitation, or sale of the Series A-3 Preferred Shares in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.

**Item 8.01. Other Events.**

On September 23, 2025, SEED issued a press release announcing the share purchase agreements, a copy of which is attached hereto as Exhibit 99.1 and incorporated herein by reference.

**Cautionary Note Regarding Forward-Looking Statements**

This Report on Form 8-K includes forward-looking statements that are not historical facts. Words such as "will," "expect," "anticipate," "plan," "believe," "design," "may," "future," "estimate," "predict," "objective," "goal," or variations thereof and variations of such words and similar expressions are intended to identify such forward-looking statements. Forward-looking statements are based on the Company's current knowledge and its present beliefs and expectations regarding possible future events and are subject to risks, uncertainties and assumptions. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of several factors including, but not limited to, difficulties raising the anticipated amount needed to finance the Company's and SEED's future operations on terms acceptable to the Company and SEED, if at all, unexpected results of clinical trials, delays or denial in regulatory approval process, results that do not meet our expectations regarding the potential safety, the ultimate efficacy or clinical utility of our product candidates, increased competition in the market, and other risks described in the Company's most recent 10-K on file with the U.S. Securities and Exchange Commission. All forward-looking statements made herein speak only as of the date of this release and the Company undertakes no obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as otherwise required by law.

**Item 9.01. Financial Statements and Exhibits.**

**(d) Exhibits.**

---

| | |
|:---|:---|
| **<u>Exhibit No.</u>** | **<u>Description</u>** |
| [99.1](exh_991.htm) | [Press Release, dated September 23, 2025](exh_991.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

#### SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **BeyondSpring Inc.** | **BeyondSpring Inc.** |
| Date: September 23, 2025 | By: | <u>/s/ Lan Huang&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u> |
|  |  | Lan Huang |
|  |  | Chairperson and Chief Executive Officer |

---

## Exhibit 99.1

**EXHIBIT 99.1**

**SEED Therapeutics Completes $30 Million Series A-3 Financing**

KING OF PRUSSIA, Pa., Sept. 23, 2025 (GLOBE NEWSWIRE) -- **SEED Therapeutics, Inc.** ("SEED"), a clinical-stage biotechnology company pioneering rational molecular glue degraders for historically undruggable disease drivers, today announced the successful completion of its **$30 million Series A-3 financing**, alongside U.S. Food and Drug Administration (FDA) clearance of its Investigational New Drug (IND) application for its lead program targeting RBM39. The company anticipates entering first-in-human clinical trials of **ST-01156** in Q1 2026.

The $30 million Series A-3 financing consists of a **$24 million first close completed in August 2024** and a **$6 million second close completed in August 2025**. In addition, SEED has received **close to $60 million in equity, as well as collaboration upfront and milestone payments combined, from its partnerships with Eli Lilly and Eisai** reflecting strong partner validation of its scientific platform.

**Lan Huang, Ph.D., SEED Co-Founder, Chairman, and Chief Executive Officer**, said:

"FDA clearance of our IND is a defining milestone for SEED, marking our transition into a clinical-stage company. ST-01156 represents the first of a new generation of rationally designed molecular glue degraders. We continue to translate innovation into meaningful therapies for patients."

**Bill Desmarais, SEED Chief Financial Officer and Chief Business Officer**, added:

"Our equity financing, together with collaboration payments from Eli Lilly and Eisai, supplement our resources to move confidently into the clinic and to continue building a broad pipeline. We have the partners, capital, and momentum to deliver on SEED's strategy."

SEED Therapeutics is a **TPD 2.0 company** that integrates structure-based drug design, computational chemistry, and chemical biology to discover molecular glues that reprogram the ubiquitin-proteasome system to degrade disease-causing proteins. Its proprietary **RITE3™ platform** has generated a growing pipeline of nine programs spanning oncology, neurodegeneration, immunology, and virology.

**About SEED Therapeutics**

SEED Therapeutics is a clinical-stage biotechnology company pioneering rationally designed molecular glue degraders to treat diseases driven by undruggable proteins. Its proprietary **RITE3™** platform enables targeted protein degradation with small-molecule precision.

SEED's lead candidate, **ST-01156**, is a brain-penetrant RBM39 degrader entering clinical development for Ewing sarcoma and other RBM39-dependent cancers.

SEED was co-founded by four scientific leaders:

* **Nobel Laureate Prof. Avram Hershko,** discoverer of the ubiquitin-proteasome system

* **Dr. Lan Huang**, solved the first E3 Ligase structure and a serial biotech entrepreneur

* **Prof. Ning Zheng** (University of Washington, HHMI Investigator), pioneer of E3 Ligase structures and coined the phrase "*molecular glue*"

* **Prof. Michele Pagano** (NYU Grossman School of Medicine, HHMI Investigator), a preeminent expert on E3 ligase biology

**SEED's investors and collaborators include Eli Lilly** and **Eisai, both of whom have been instrumental in supporting** SEED's mission to unlock undruggable disease targets. The company's pipeline includes nine programs across oncology, neurodegeneration, immunology, and virology.

**Media & Investor Contact**

IR@seedtherapeutics.com

PR@seedtherapeutics.com

<u>www.seedtherapeutics.com</u>